|
[1]
|
Ljungberg, B., et al. (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 75, 799-810. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
王宁, 李明义, 杨培谦. 肾癌预后分析系统概述[J]. 中国医刊, 2016, 51(9): 26-28. [Google Scholar] [CrossRef]
|
|
[3]
|
Singh, D. (2021) Current Updates and Future Perspec-tives on the Management of Renal Cell Carcinoma. Life Sciences, 264, Article ID: 118632. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
马巍巍, 王龙信. 转移性肾癌免疫治疗的新进展[J]. 国际泌尿系统杂志, 2022, 42(2): 349-352.
|
|
[5]
|
熊斌, 鲁伟. 转移性肾癌治疗的现状和进展[J]. 中华泌尿外科杂志, 2021, 42(4): 308-311.
|
|
[6]
|
Abe, H. and Kamai, T. (2013) Recent Advances in the Treatment of Metastatic Renal Cell Carci-noma. International Journal of Urology, 20, 944-955. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Brady, L.W., O’Neill, E.A. and Farber, S.H. (1997) Unusual Sites of Metastases. Seminars in Oncology, 4, 59-64.
|
|
[8]
|
Lew, M., Foo, W.-C. and Roh, M.H. (2014) Diagnosis of Metastatic Renal Cell Carcinoma on Fine-Needle Aspiration Cytology. Archives of Pathology & Laboratory Medicine, 138, 1278-1285. [Google Scholar] [CrossRef]
|
|
[9]
|
Motzer, R.J., Nanus, D.M., Russo, P. and Berg, W.J. (1997) Renal Cell Carcinoma. Current Problems in Cancer, 21, 185-232. [Google Scholar] [CrossRef]
|
|
[10]
|
Jantzer, P. and Schendel, D.J. (1998) Human Renal Cell Carcinoma Antigen-Specific CTLs: Antigen-Driven Selection and Long-Term Persistence in Vivo. Cancer Research, 58, 3078-3086.
|
|
[11]
|
Clark, P.E. (2009) The Role of VHL in Clear-Cell Renal Cell Carcinoma and Its Relation to Targeted Therapy. Kidney International, 76, 939-945. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Malhotra, K.P., Gupta, A., Shukla, S., Agarwal, G.R. and Malhotra, H.S. (2021) Metastases from Renal Cell Carcinoma—Report of Three Unpre-dictable Cases and Literature Review. Indian Journal of Cancer, 58, 273-277.
|
|
[13]
|
周莉, 盛锡楠. 晚期肾癌的免疫治疗进展与述评[J]. 肿瘤防治研究, 2020, 47(3): 149-153. [Google Scholar] [CrossRef]
|
|
[14]
|
Braun, D.A., et al. (2021) Beyond Conventional Im-mune-Checkpoint Inhibition—Novel Immunotherapies for Renal Cell Carcinoma. Nature Reviews Clinical Oncology, 18, 199-214. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Hirsch, L., Flippot, R., Escudier, B. and Albiges, L. (2020) Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. Drugs, 80, 1169-1181. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
McKay, R.R., Bossé, D. and Choueiri, T.K. (2018) Evolving Systemic Treatment Landscape for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 36, 3615-3623. [Google Scholar] [CrossRef]
|
|
[17]
|
Rini, B.I., et al. (2019) Atezolizumab plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (Immotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial. Lancet, 393, 2404-2415. [Google Scholar] [CrossRef]
|